A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 34
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : MK
Long Form : montelukast
No. Year Title Co-occurring Abbreviation
2021 Leukotriene D4 Upregulates Oxidized Low-Density Lipoprotein Receptor 1 and CD36 to Enhance Oxidized LDL Uptake and Phagocytosis in Macrophages Through Cysteinyl Leukotriene Receptor 1. LTD4, oxLDL
2021 Montelukast and Coronavirus Disease 2019: A Scoping Review. COVID-19, SARS-CoV-2
2020 Montelukast improves bronchopulmonary dysplasia by inhibiting epithelial‑mesenchymal transition via inactivating the TGF‑beta1/Smads signaling pathway. BPD, Col I, LW/BW, MLI, MMP, RAC, TGF
2019 Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. DMARDs, FDA, HCQ, HPTLC, MTX, QbD, Rf, SSZ
2018 Effects of anti-allergic drugs on T cell-mediated nasal hyperresponsiveness in a murine model of allergic rhinitis. AR, CHL, DEX, NALF, NALT, NHR
2018 Montelukast attenuates rotenone-induced microglial activation/p38 MAPK expression in rats: Possible role of its antioxidant, anti-inflammatory and antiapoptotic effects. p38 MAPK, PD, TH
2017 Resveratrol and Montelukast Alleviate Paraquat-Induced Hepatic Injury in Mice: Modulation of Oxidative Stress, Inflammation, and Apoptosis. PQ, RES
2016 Chemical Genomics Identifies the PERK-Mediated Unfolded Protein Stress Response as a Cellular Target for Influenza Virus Inhibition. ---
2016 Development of an enantioselective capillary electrophoretic method for the simultaneous determination of montelukast enantiomeric and diastereoisomeric forms and its main degradation product. ---
10  2016 Electrosprayed Montelukast/poly (lactic-co-glycolic acid) particle based coating: A new therapeutic approach towards the prevention of in-stent restenosis. DESs, HCAECs, HCASMCs, LTs, PCI
11  2014 Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability. DMSO, ISI, ISM, NMP, PLGA
12  2014 HPTLC method for direct determination of gemifloxacin mesylate in human plasma. GFX, HPTLC
13  2014 Influence of montelukast on cisplatin-induced experimental acute renal failure. ARF, CIS
14  2013 Protective effect of high-dose montelukast on salbutamol-induced homologous desensitisation in airway smooth muscle. BSMC, PDE
15  2013 Protective effect of montelukast which is cysteinyl-leukotriene receptor antagonist on gentamicin-induced nephrotoxicity and oxidative damage in rat kidney. GEN, MDA, NO
16  2013 Restoration of the normal Clara cell phenotype after chronic allergic inflammation. AB/PAS, BUD
17  2012 Montelukast inhibits leukotriene stimulation of human dendritic cells in vitro. moDCs
18  2010 Montelukast during primary infection prevents airway hyperresponsiveness and inflammation after reinfection with respiratory syncytial virus. AHR, CysLT, RSV
19  2010 Montelukast prevents vascular endothelial dysfunction from internal combustion exhaust inhalation during exercise. FMD, LT, PL, PM
20  2010 Montelukast reduces eosinophilic inflammation by inhibiting both epithelial cell cytokine secretion (GM-CSF, IL-6, IL-8) and eosinophil survival. E-CM, FBS, NM
21  2010 Randomized open comparison of montelukast and sublingual immunotherapy as add-on treatment in moderate persistent asthma due to birch pollen. SLIT
22  2009 [Effects of leukotriene receptor antagonists on vascular endothelial growth factor and its receptors in a sensitized rat model]. ELISA, VEGF
23  2009 [Effects of montelukast and BCG-PSN on the expression of STAT5b mRNA and IL-4 mRNA in blood mononuclearcells of rats with asthma]. BCG-PSN, EOS, IFN-gamma, IL-4, OVA, STAT5b
24  2008 Fluticasone or montelukast for preschool children with asthma-like symptoms: Randomized controlled trial. FOT, FP
25  2007 Sparing effect by montelukast treatment for chronic graft versus host disease: a pilot study. CysLTs, GVHD, SCT
26  2006 The effects of low dose leukotriene receptor antagonist therapy on airway remodeling and cysteinyl leukotriene expression in a mouse asthma model. CysLT1, OVA
27  2004 Comparison study between the mechanisms of allergic asthma amelioration by a cysteinyl-leukotriene type 1 receptor antagonist montelukast and methylprednisolone. CysLT, LAR, MP, OVA
28  2004 [Effect of montelukast on the apoptosis of lymphocytes in asthmatic rats and its molecular mechanism]. DXM, OVA, TUNEL
29  2004 [The effect of montelukast on airway remodeling and the expression of interleukins and transforming growth factor-beta2 mRNA]. BALF, IL-4, OVA, RT-PCR
30  2003 Anti-inflammatory effects of high-dose montelukast in an animal model of acute asthma. BAL, OVA, Th2
31  2003 Effects of cysteinyl leukotrienes in small human bronchus and antagonist activity of montelukast and its metabolites. CysLTs
32  2003 Protective effect of leukotriene receptor antagonist montelukast on smoking-induced lung injury in Wistar rats. CS, LMC, LTR-1AT, LTs, Sva.pa
33  2002 Leukotriene receptor antagonists (Montelukast) in the treatment of asthma crisis: preliminary results of a double-blind placebo controlled randomized study. ER, PL
34  1999 Montelukast, a leukotriene receptor antagonist, inhibits the late airway response to antigen, airway eosinophilia, and IL-5-expressing cells in Brown Norway rats. BAL, CysLT